Farmas USA

ARRY

Phase 3 COLUMBUS trial NDA of binimetinib, in combination with encorafenib, for the treatment of BRAF-mutant melanoma, which remains on track for mid-2017.

NDA submission of binimetinib, in combination with encorafenib, for BRAF-mutant melanoma expected in mid-2017

OMER

Esto es de octubre, no sé si se ha producido o no

the company is also pursuing breakthrough therapy designation for OMS721 in IgA nephropathy and in HSCT-TMAs, neither of which has any approved treatment

Barriendo stop loss antes de BO. ?

Cempra Withdraws Solithromycin Marketing Authorization Application in Europe

https://globenewswire.com/news-release/2017/03/28/945758/0/en/Cempra-Withdraws-Solithromycin-Marketing-Authorization-Application-in-Europe.html

NVIV

Esta hay que empezar a mirársela en serio. Presentará el papeleo a finales de este año/principios del siguiente para la aprobación.

patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement

the patient has also experienced substantial improvements in sensory and motor function. Prior to surgery, the subject had a T12 neurological level of injury with some spared bilateral sensation on the front of the legs and unilateral palpable hip muscle contraction but no ability to move either leg. The patient had no sensory function on the front of the legs from just below the knee and no sensory function on the back of the body from just below the waist. At the two-month visit, the patient was able to move his hips and knees bilaterally and had regained at least some sensory function in almost all regions across the lower legs, feet, and the back of the body from just below the waist.

https://www.streetinsider.com/Corporate+News/Invivo+Therapeutics+%28NVIV%29+Announces+Seventh+Patient+Conversion+in+The+INSPIRE+Study+of+Neuro-Spinal+Scaffold/12712485.html?si_client=intbro

nviv

en 3.75 me quedé esperando días atrás :(

DEPO y demás opiáceos, por si alguien se pregunta por qué están en caída (antes de darse la vuelta el índice).

Opioid epidemic: Senate committee opens probe of five big painkiller makers

The investigation will explore whether pharmaceutical manufacturers — at the head of the opioids pipeline — have contributed to opioid over-utilization and over-prescription as overdose deaths in the last 15 years have approached nearly 200,00

http://www.cnbc.com/2017/03/28/senate-committee-opens-probe-of-five-big-opioid-makers.html

Carta:

https://t.co/y9VTH83iHh

rgls

cagada no vender en after ayer  o pre hoy, a esperar que vuelva a intentar  la zona de 2$ y resistan los 1.50

CEMP

underperform rating reiterated at Robert W. Baird. $2.00 PT

Funding cuts (in millions) requested by White House

NIH: ↓ $1,232

CDC: ↓ $314 (programs de salud)

FDA: ↓ $40